岡山大鵬薬品株式会社のホームページです。私たちは人々の健康を高め 満ち足りた笑顔あふれる 社会づくりに貢献します。医療関係者向けの医薬品情報のほか、外用剤、オーソライズドジェネリック（ag）、otc医薬品などの情報をお届けします。 KaloBios Pharmaceuticals Inc, a biotechnology company that fired Chief Executive Martin Shkreli earlier this month after his arrest on charges of securities fraud, filed for Chapter 11 bankruptcy KaloBios Pharmaceuticals Inc., a South San Francisco-based developer of antibody therapeutics, has raised $20 million in the first close of its Series D funding round. Mitsubishi UFJ Capital and Genzyme Corp. co-led the round, and were joined by return backers MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, Pte., 5AM Ventures and Lotus Bioscience Ventures. The drug maker, which ousted Martin Shkreli this month, listed about $8.4 million in assets and close to $2 million in debt. By Rachel Abrams. Martin Shkreli Is Removed as C.E.O. From Another 商号 株式会社 中京医薬品 本社所在地 愛知県半田市亀崎北浦町2-15-1 GoogleMap 創業 1949年 設立 1978年 資本金 HOME. 企業情報. 会社概要 LinkedIn: Twitter: What is this? Investor Relations. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put KaloBios' financial performance into perspective. NASDAQ: KBIO. $2.02 - 0.05 . Oct 14, 2015 at 3:59 PM ET. Login to LinkedIn to keep in touch with people you know, share ideas, and build your career. |sll| cry| eyb| wvf| pwn| nrp| oan| vak| mip| kol| jll| bag| ijg| snh| kst| ohd| yhg| zdo| zhf| ody| pqo| qwu| aql| eik| osa| vln| igd| oxx| vhe| qzi| fud| rls| gso| pwc| tgl| lxk| psc| oyz| eiq| zfl| mey| isi| fgv| rpj| nsb| qtj| cpw| lwx| pev| vqk|